Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 15/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1088358 | 1.00 | UGCG (0.71) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL13081778 | 1.00 | UGCG (0.71) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL14069053 | 1.00 | UGCG (0.71) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL13098312 | 0.93 | UGCG (0.63) | UGCGPTGS1HTR1AOPRM1KDM4E | |
| SCHEMBL19354952 | 0.92 | UGCG (0.62) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL23731734 | 0.91 | UGCG (0.69) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL22463696 | 0.90 | UGCG (0.70) | UGCGPTGS1HTR1AOPRM1KDM4E | |
| SCHEMBL22463695 | 0.90 | UGCG (0.70) | UGCGPTGS1HTR1AOPRM1KDM4E | |
| SCHEMBL7993471 | 0.90 | UGCG (0.58) | UGCGPTGS1HTR1AOPRM1HTT | |
| SCHEMBL23731735 | 0.89 | UGCG (0.69) | UGCGPTGS1HTR1AOPRM1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697644-B2 | Process for synthesis of eliglustat and intermediate compounds thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2023-07-11 | — | — | US | disclosed |
| US-11697644-B2 | Process for synthesis of eliglustat and intermediate compounds thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2023-07-11 | — | — | US | disclosed |
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3611171-A1 | METHOD FOR SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2020-02-19 | — | — | EP | disclosed |
| US-20200031808-A1 | PROCESS FOR SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2020-01-30 | — | — | US | disclosed |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2019-09-12 | — | — | US | disclosed |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-9988364-B1 | Process for synthesis of Eliglustat and intermediate compounds thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9988364-B1 | Process for synthesis of Eliglustat and intermediate compounds thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-20100048642-A1 | METHODS FOR TREATING COGNITIVE DISORDERS | ALLERGAN, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20090318499-A1 | COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITY | ALLERGAN, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090281085-A1 | 3-(4-FLUOROPHENYL)-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC ACTIVITY | ALLERGAN, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090088433-A1 | METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. | 2009-04-02 | — | — | US | disclosed |
| US-20090036436-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | ALLERGAN, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20080312236-A1 | 3-Heteroaryl-3-Hydroxy-2-Amino-Propyl Amines And Related Compounds Having Analgesic And/Or Immuno Stimlant Activity | EXONHIT THERAPEUTICS SA (FR) | 2008-12-18 | — | — | US | disclosed |
| WO-2008109286-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-7265228-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070203223-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2007-08-30 | — | — | US | disclosed |
| US-7196205-B2 | Synthesis of amino ceramide-like compounds; for treating Tay-Sachs, Gaucher's or Fabry's disease; amenable to large scale preparations | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312236-A1 | 3-Heteroaryl-3-Hydroxy-2-Amino-Propyl Amines And Related Compounds Having Analgesic And/Or Immuno Stimlant Activity | OPRL1, OPRM1, MRGPRX2 | UGCG 2783/4885PTGS1 85/4885HTR1A 188/4885 |
| US-20090088433-A1 | METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | OPRL1, OPRK1, AADAT | UGCG 4208/4885PTGS1 56/4885HTR1A 81/4885 |
| US-20090036436-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | OPRL1, HCAR2, OPRM1 | UGCG 4112/4885PTGS1 168/4885HTR1A 88/4885 |
| US-20090281085-A1 | 3-(4-FLUOROPHENYL)-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC ACTIVITY | OPRL1, OPRK1, OPRM1 | UGCG 3951/4885PTGS1 17/4885HTR1A 271/4885 |
| US-11697644-B2 | Process for synthesis of eliglustat and intermediate compounds thereof | EPOR, FGFR1, ABL1 | UGCG 555/4885PTGS1 1241/4885HTR1A 3787/4885 |
| US-20090318499-A1 | COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITY | OPRK1, OPRM1, OPRL1 | UGCG 3478/4885PTGS1 64/4885HTR1A 1217/4885 |
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | UGCG 2/4885PTGS1 128/4885HTR1A 3038/4885 |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, UGCG, GBA2 | UGCG 2/4885PTGS1 128/4885HTR1A 3038/4885 |
| US-20070203223-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | UGCG, UGGT1, DPAGT1 | UGCG 1/4885PTGS1 2317/4885HTR1A 3504/4885 |
| US-20100048642-A1 | METHODS FOR TREATING COGNITIVE DISORDERS | CHAT, SLC18A3, SLC18A2 | UGCG 556/4885PTGS1 2164/4885HTR1A 118/4885 |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | UGCG 2/4885PTGS1 290/4885HTR1A 4274/4885 |
| US-20200031808-A1 | PROCESS FOR SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | COASY, ELL, CYP3A4 | UGCG 442/4885PTGS1 970/4885HTR1A 4060/4885 |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | UGCG 2/4885PTGS1 130/4885HTR1A 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.